Form 4: Verastem Director Brian Stuglik Receives Significant Equity Compensation Package

Verastem, Inc. Director Brian M. Stuglik reported the acquisition of 8,333 restricted stock units and 12,500 stock options as part of his compensation, aligning his interests with the company's long-term performance.

Summary

• Brian M. Stuglik, a Director of Verastem, Inc. (VSTM), reported transactions on May 22, 2025, involving the acquisition of company securities.
• He acquired 8,333 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.00 per share.
• Following this transaction, Mr. Stuglik beneficially owns 102,920 shares of Common Stock.
• He also acquired 12,500 stock options with an exercise price of $7.48 per share, which expire on May 22, 2035.
• After this transaction, Mr. Stuglik beneficially owns 12,500 stock options.
• Both the RSUs and stock options vest in twelve equal installments, with the first eleven installments vesting monthly from June 2025 to April 2026.
• The final installment for both the RSUs and stock options will vest on the earlier of (i) the day before the 2026 Annual Meeting of Stockholders or (ii) May 31, 2026.
• Vesting is contingent upon Mr. Stuglik's continued service as a director of Verastem, Inc. on each vesting date.
• The RSU grant was made under the Issuer's Amended and Restated 2021 Equity Incentive Plan.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 7

Explanation: The document reports standard equity compensation for a director, which is a positive for corporate governance as it aligns management's interests with shareholders. It does not indicate any negative operational or financial news for the company.

Positives

• The grant of restricted stock units and stock options to a director aligns their financial interests directly with the long-term performance and shareholder value of Verastem, Inc.
• Equity compensation is a standard practice for retaining and incentivizing key personnel, including directors, in publicly traded companies.
• The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-arranged trading strategy designed to comply with insider trading regulations.

Risks

• The vesting of both the RSUs and stock options is conditional upon Brian M. Stuglik's continued service as a director of Verastem, Inc. until the respective vesting dates.
• The value of the stock options is dependent on the future market price of Verastem's common stock exceeding the exercise price of $7.48.

Future Outlook

The future outlook for the reporting person's equity holdings is tied to the vesting schedule, which extends through May 2026, contingent on continued service as a director. The stock options have a long-term expiration date of May 2035, providing a significant window for potential value realization.

Management Comments

• The filing was signed by Daniel Calkins, Attorney in Fact for Brian M. Stuglik.

Industry Context

Equity grants, including RSUs and stock options, are a common and widely accepted form of compensation for directors and executives across various industries, particularly in the biotechnology and pharmaceutical sectors where long-term value creation is paramount. This practice aims to align the interests of company leadership with those of shareholders.

Comparison to Industry Standards

• The structure of equity compensation, involving both RSUs and stock options with multi-year vesting schedules, is consistent with typical compensation packages for non-executive directors in the biotechnology industry.
• The use of a Rule 10b5-1 plan for these grants is a standard corporate governance practice to ensure compliance with insider trading regulations and provide a clear framework for future equity transactions.

Corporate Governance

Related Party Transactions

• The acquisition of RSUs and stock options by Brian M. Stuglik, a director of Verastem, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially leading to more focused efforts on long-term value creation.
• Employees: No direct impact on general employees is indicated, but it reflects the company's compensation philosophy for its leadership.

Next Steps

• Brian M. Stuglik's continued service as a director of Verastem, Inc. is required for the vesting of the granted RSUs and stock options.
• The company will continue to report any changes in beneficial ownership by insiders through subsequent Form 4 filings.

Key Dates

Recommendation

Keywords

Verastem, VSTM, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, Brian Stuglik, Corporate Governance, Rule 10b5-1